Real-world data on treatment persistence and measures to minimize cardiovascular risk in rheumatic patients using upadacitinib
In real-world clinical settings, UPA persistence is lower among RA patients who have received prior IL-6i treatment. Treatment strategies to avoid UPA in patients with CVR appear to be primarily driven by pivotal safety studies rather than regulatory guidance.
Authors
- Carlos Rodríguez Lozano
- Alicia García-Dorta
- Vanesa Hernández-Hernández (ORCID: https://orcid.org/0000-0003-1306-8461)
- Federico Díaz‐González (ORCID: https://orcid.org/0000-0002-4139-9295)
- Enrique González‐Dávila (ORCID: https://orcid.org/0000-0002-0781-9161)
- Cristina Martínez González (ORCID: https://orcid.org/0000-0002-0369-4920)
- Andrea Hernández-Martín
- Cristina Rodríguez-Regalado
- Elena Naveda-González
- Sonia Peña-Montelongo
Institutions
- Universidad de La Laguna (ES)
- Hospital Universitario de Canarias (ES)
- Hospital Universitario Nuestra Señora de Candelaria (ES)
- Hospital Universitario de Gran Canaria Doctor Negrín (ES)
- Hospital Universitario Virgen de las Nieves (ES)
Publication Details
- Journal
- Lara D. Veeken
- Published
- 2025-10-21
- DOI
- https://doi.org/10.1093/rheumatology/keaf547
- Primary Topic
- Rheumatoid Arthritis Research and Therapies
- Type
- article
- Field-Weighted Citation Impact
- 0.00